CDT Equity (CDT)
Develops and out-licenses repurposed clinical assets through solid-form chemistry, computational analysis, and patent creation.
Something off on this page? Send us feedback.
Develops and patents new forms and indications for previously tested pharmaceutical compounds, then seeks licensing partners for later development and commercialization. Its lean, outsourced model centers on AstraZeneca-licensed assets, solid-form chemistry, computational analysis, and a related investment in Sarborg.
Develops clinical assets and licensing-ready intellectual property from previously tested or underused compounds, applying solid-form and cocrystal chemistry with computational analysis to reposition molecules and form new patent positions. The pipeline includes AstraZeneca-licensed glucokinase activators AZD1656 and AZD5658, the myeloperoxidase inhibitor AZD5904, and tapinarof combination and cocrystal applications.
Operates from corporate administration in Naples, Florida and a Cambridge, UK laboratory, using a lean internal team alongside consultants, contract research organizations, and external manufacturers. It seeks to out-license data and IP packages to partners for later clinical work, approval, manufacturing, and commercialization in return for upfront payments, milestones, and royalties.
Has no approved products, sales force, or product revenue. Its model depends on continuing access to the licensed AstraZeneca assets, patent applications that establish protectable positions, funding, and partners able to develop and commercialize the programs.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 28, 2026Cash & short-term investments $348.7M · Total debt $1.32B · Total assets $3.50B · Shareholders' equity $1.38B
- Revenue
- $750.2M
- Operating income
- $117.4M
- Net income
- $68.5M
No dividends on record.
| Institutions381 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | ≈ 852.36% | 4.14M shares | |
| Insiders7 holders · as of Sep 2, 2026 | 1,176.66% | 5.72M shares | |
| Strategic holders1 holder · as of May 7, 2025 | 0.01% | 62 shares | |
| Adds to | 2,029.03% |
485.8K company shares as of Aug 26, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (39.08M in the company's Sep 3, 2026 report, 485.8K elsewhere); stakes use the report.
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 2,029.03%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Andrew Regan1Insiderdirector, officer: Chief Executive Officer | 1,171.78% | 5.69M | Form 4filed Sep 2, 2026 ↗ |
BlackRock, Inc.Institution | 105.83% | 5.14M | 13Fas of Jun 30, 2026 |
FMR LLCInstitution | 83.28% | 4.05M | 13Fas of Jun 30, 2026 |
Price T Rowe Associates Inc /MD/Institution | 71.45% | 3.47M | 13Fas of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 56.78% | 2.76M | 13Fas of Jun 30, 2026 |
| See all 25 → | |||
- Andrew Regan reports a block also reported by Dimensional Fund Advisors LP; it is counted once, under Dimensional Fund Advisors LP.
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 28, 2026 | Andrew Regan | director, officer: Chief Executive Officer | −290 | $0.0001 |
| Jun 18, 2026 | Mark Andrew Taylor | 10 percent owner | −2,068,000 | $1.42 |
Not reported.